A unified semi‐quantitative method to assess both amyloid (CERAD) and tau (Braak stage) deposition was used to classify all cases, defined by these post mortem pathological criteria, as neurologically healthy controls, AD, and PSP (UPenn cohort: N = 28 controls, 21 AD, and 18 PSP) (Table S2). The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.